Intralesional Injection of STS in Treatment of Calcinosis
Status:
RECRUITING
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
Phase:
PHASE2
Details
Lead Sponsor:
Robyn T. Domsic, MD, MPH
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)